Understanding Rheumatic Side Effects from Immunotherapy
This study aims to understand the experiences of people who develop rheumatic immune-related adverse events (side effects like arthritis or polymyalgia rheumatica) after receiving immune checkpoint inhibitor immunotherapy. Researchers want to learn about the severity and impact of these side effects on your daily life. You may be able to join if you are 18 or older, speak English, and have a diagnosis from a rheumatologist of inflammatory arthritis or polymyalgia rheumatica that developed after immune checkpoint inhibitor therapy. The study will measure safety and adverse events over an average of one year to see what success looks like. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will gather information without giving any specific treatments. It plans to include about 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Y. Jeff Li, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Safety and Adverse Events (AEs).Through study completion; an average of 1 year
Incidence of Adverse Events